Leerink analyst Paul Matteis raised his price target for Zogenix to $54 from $54 and reiterates an Outperform rating on the shares in a research note titled "Are Investors Sleeping on ZGNX's Path to ZX008 IP Protection?" The analyst's research makes him optimistic regarding the path for Zogenix to extend the exclusivity period of ZX008 in Dravet syndrome beyond the consensus expectation of seven-and-a-half years of orphan/pediatric drug exclusivities. He sees a "reasonable chance" that potential ZX008 generic drug manufacturers could be delayed as a result of recently issued method of treatment patents. Matteis expects this extension story will continue to develop during the course of 2018.